RedHill Biopharma (RDHL) Enterprise Value (2016 - 2025)
Historic Enterprise Value for RedHill Biopharma (RDHL) over the last 15 years, with Q2 2025 value amounting to -$4.6 million.
- RedHill Biopharma's Enterprise Value rose 5286.21% to -$4.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$4.6 million, marking a year-over-year increase of 5286.21%. This contributed to the annual value of -$6.0 million for FY2024, which is 431.06% up from last year.
- Latest data reveals that RedHill Biopharma reported Enterprise Value of -$4.6 million as of Q2 2025, which was up 5286.21% from -$6.0 million recorded in Q4 2024.
- RedHill Biopharma's 5-year Enterprise Value high stood at -$4.6 million for Q2 2025, and its period low was -$76.0 million during Q1 2021.
- For the 5-year period, RedHill Biopharma's Enterprise Value averaged around -$27.1 million, with its median value being -$22.1 million (2022).
- Its Enterprise Value has fluctuated over the past 5 years, first crashed by 6486.16% in 2021, then soared by 7206.85% in 2023.
- Over the past 5 years, RedHill Biopharma's Enterprise Value (Quarter) stood at -$29.5 million in 2021, then grew by 23.35% to -$22.6 million in 2022, then skyrocketed by 72.07% to -$6.3 million in 2023, then grew by 4.31% to -$6.0 million in 2024, then rose by 23.35% to -$4.6 million in 2025.
- Its Enterprise Value stands at -$4.6 million for Q2 2025, versus -$6.0 million for Q4 2024 and -$9.8 million for Q2 2024.